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ABSTRACT
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EFFECTS DURING OSTEOBLAST DIFFERENTIATION IN A 
MESENCHYMAL STEM CELL MODEL 
By Jochen Alexander Granja Vasquez, B.S.
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Musculoskeletal diseases, in particular osteoporosis, are increasingly becoming 
more prevalent in the U.S. due to the ageing population (Figure1).  It is estimated that one-
sixth of 300 million people in U.S. suffer from bone disorders or loss.  About 10 million of 
those people above age 50 suffer from osteoporosis.  Patients that suffer from osteoporosis 
have high morbidity and mortality rates.  For instance, patients have decreased bone 
x
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mineral density (BMD), a measurement of bone density that reflects the strength of bone as 
represented by calcium content.  A decrease in BMD typically leads to an increased risk of 
bone fractures.  In particular, hip fractures have an associated 20% mortality rate 1 year 
after injury among senior citizens 1.   Patients that suffer from musculoskeletal diseases and 
from bone injuries, not associated with disease, account for 130 million hospital visit per 
year.  Not to mention, 245 billion dollars of healthcare expenditure 2.  
Over that last 30 years, there has been much improvement in the field of bone 
research and its application to medicine.  It has changed the quality of life and prolonged 
the life expectancy of patients suffering from bone disease.  However, many details remain 
unknown about the underlying mechanism that control bone metabolism, formation, and 
healing.  Furthermore, current effective therapies to combat bone disorders have 
limitations including unwanted side effects and prohibitive costs.  For example, treatment 
with glucocorticoids which is a known inducer of osteoblastogenesis in vitro has been 
shown to produce an osteoporotic phenotype in vivo.  Recognizing the importance of bone 
health and its affordability to the public makes the advancement of therapeutic targets 
work worth doing.  Work in this field will eventually lead to the prevention, treatment, and 
cure for bone disease.  
A potential therapeutic candidate that maybe involved directly or indirectly with 
bone formation is secreted phosphoprotein-24 (Spp24).  The following research aims to 
establish an importance and role for Spp24 in bone differentiation.  A novel antibody that 
detects Spp24 which we have developed and characterized, has allowed us to feasibly 
study the protein.  Our results demonstrate localization of Spp24 in different tissue, the 
xii
processing of the protein during osteoblastogenesis, and have allowed us to conceptualize 
possible functions based on our data.
xiii
xiv
Figure 1.  Prevalence of Osteoporosis and/or Low Bone Mass in Both
Sexes 50 Years of Age or Older
Source: Bone Health and Osteoporosis:  A Report of the Surgeon General
Data from the National Health and Nutrition Examination Survey (NHANES) is 
conducted by National Center for Health Statistics, a part of the Center for Disease Control 
and Prevention.  This survey is conducted on a nationally representative sample of 
Americans.  As part of NHANES, BMD of the hip was measured in 14,646 men and 
women over 20 years of age throughout the United States from 1988 until 1994.  Based on 
the WHO definitions of normal to osteoporotic BMD, a percentage was derived for those 
individuals above the age of 50 who have osteoporosis and low bone mass.  These 
percentages where then applied to the total population of patients over the age of 50. 
Projections for 2010 and 2020 are base on population forecasts for these years due to both 
expected growth and ageing of population. 
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CHAPTER 1
GENERAL INTRODUCTION
Bone Biology and Physiology
The skeleton is a highly dynamic and metabolic organ responsible for a vast variety 
of functions including structural support of the body, locomotion, protection of vital 
organs, and maintenance of calcium/phosphorous homeostasis.  It is composed of three cell 
types having different functions. The first cell type is the bone forming osteoblast which 
secretes an inorganic/organic-matrix.  The inorganic matrix is known as hyroxyapatite 
(Ca10(PO4)6(OH)2).  The organic portion of the matrix, know as osteoid, is composed of 
various collagenous (particularly collagen type I) and non-collagenous proteins.    The 
second cell type is an osteoclast.  It is involved in breaking down bone tissue so that the 
metabolites can be taken into the extracellular fluid through a process known as resorption. 
The last cell is an osteocyte and is a former osteoblast.  After osteoblasts have secreted the 
matrix the cells become embedded in their own bone matrix that has mineralized. 
Osteocytes primarily maintain the integrity of bone through their cytoplasmic extensions 
which form a network.  This network serves to acquire nutrients, remove waste, and as a 
mechanosensory mechanism to sense different types of stimuli.  Osteoblast and osteoclast 
cells engage in a coupled rate constant cycle of formation and resorption known as 
remodeling or turnover.  This remodeling process is responsible for homeostasis, growth, 
1
2and repair of the skeleton.  A peak BMD is reached during adolescence and early 
adulthood via the remodeling process.  After which, around the age of 25-30 the process of 
formation begins to slow and resorption remains constant or increases.  Eventually the 
constant or increased rate of resorption causes a negative balance between the coupled 
processes that result in phenotypic states known as osteopenia (bone thinning or bone loss) 
and a diseased state known as osteoporosis (severe bone loss).  
There are two mechanism of bone formation during development.  The first is 
known as intramembranous ossification which involves the recruitment of mesenchymal 
stem cells (MSC’s) that differentiate into osteoblast.  Intramembranous ossification is 
responsible for the development of flat bones like the skull and mandible.  The second 
mechanism is endochondral ossification and requires cells to first differentiate into 
chondrocytes.  After chondrocytes have finished building a template for bone architecture, 
they are later replaced by invading osteoblast to mineralize the bone and is the main 
mechanism for long bone development 3.
The metabolic and homeostatic functions of bone are tightly regulated by 
hormones, cytokines, and transcription factors via local (autocrine and paracrine) and 
endocrine signaling.  These signaling molecules (i.e., growth hormone (GH), bone 
morphogenetic protein (BMP), and secreted phosphoprotein-24 (Spp24) Table 1.) effect 
bone development, proliferation, differentiation, turnover, and fracture healing.  Further 
information of some specific molecules that regulate bone metabolism will be discussed in 
subsequent sections of the general introduction.
3 Although, many molecules have been implicated in being involved, directly or 
indirectly, associations of these molecules with well-defined bone phenotypes and 
functions is not well described.  In particular, Spp24 is a relatively novel protein that is not 
well understood, and may be an important signaling mediator controlling bone formation 
including differentiation, development, and fracture healing.
Bone Pathologies
There is a large number and variety of bone diseases.  All of which cause 
phenotypic abnormal bones.  Risk factors of bone diseases include genetics, age, diet, 
exercise, and hormonal imbalance.  This section will only briefly introduce three.  
Osteoporosis is the most common of these diseases and could be the result of one 
or more of the aforementioned risk factor.  Typically osteoporosis is associated with low 
BMD and characteristically has higher osteoclastic than osteoblastic activity.  Osteoporosis 
greatly increases the risk of fractures particularly of the hip, spine, and wrist.   Typically 
osteoporosis does not present any symptoms unless there is a bone fracture. 
The second most common bone disease is Paget’s disease.  Paget’s has been found 
to have strong familial predispositions.  Characteristics of Paget’s include overactive 
osteoclast activity which the body tries to compensate by increasing osteoblastic activity. 
This ultimately leads to disorganized formation and structure of bone.  Although both 
Paget’s and Osteoporosis share common characteristics including increased osteoclastic 
activity and fragile bones, they are completely different disease.  Difference between 
Paget’s and Osteoporosis include the areas they affect, bone structure, and symptoms. 
4Paget’s normally affects one or two bones in the body whereas osteoporosis affects the 
whole skeleton.  Since both diseases can be associated with negative bone loss it might be 
easy to assume that bone structure is similar.  Although this can be the case, Paget’s can 
also cause an enlargement of a bone, part of the compensation mechanism already 
discussed, whereas Osteporosis causes net negative bone loss weakening bone structure. 
Finally, symptoms of Paget’s include hearing loss, vision impairment, and pain from 
pinched nerves or inflamed joints associated with the enlargement of particular bones.  As 
mentioned, Osteoporosis is typically asymptomatic.
Lastly, Rickets (which affects children) and Osteomalacia (which affects adults) are 
related diseases that are not very common in the United States.  These diseases are 
typically caused by vitamin D insufficiency due to lack of sun exposure or nutrition. 
Vitamin D is central to the mineralization of bone.  Therefore, an insufficiency would lead 
do abnormal bone development 1.
  
Stem Cells and Bone Marrow Derived Mesenchymal Stem Cells
Stem cells are only cell type with the unique ability to both proliferate without 
limitation (i.e. self-renewal) and differentiate into a specific cell lineage (i.e. totipotent 
cells or unlimited cell plasticity).  Besides being the cells where all organisms originate 
from, in the adult human being they are the body’s natural healers capable of repairing, 
replacing, or regenerating damaged or diseased tissue.  For this reason, stem cells are the 
target and future for tissue engineering and regenerative medicine.  The ethical issues and 
government sanctions surrounding the use and isolation of embryonic stem cells has 
5resulted in research efforts to focus on tissue specific adult stem cells which do not have 
these limitations.  Of the adult stems cells suitable for tissue engineering and regenerative 
medicine, adult human bone marrow derived (MSC’s) are the primary focus for this study. 
They have been known to differentiate into various tissues like bone, cartilage, fat, and 
muscle depending upon the host of signaling cues it receives from cytokines and growth 
hormone in an endocrine, paracrine, and autocrine fashion 4.  Also, other studies show 
MSC’s ability to trans-differentiate into other lineages (i.e. hepatocytes & neurocytes) 5. 
This demonstrates the pluripotent potential MSC’s have and successive impact in field of 
tissue engineering and regenerative medicine. 
The term mesenchyme, as found in the Online Etymology Dictionary, is derived 
from greek words “meso” and “khymos” meaning “middle” and “juice,” respectively. 
Found in the middle of the three germ layers of mammalian systems, MSC’s originate 
from the mesoderm which gives rise to connective tissue.  Although MSC’s come from the 
mesoderm, proliferation continues in repositories of the adult body, namely bone marrow 4. 
Mesenchymal stem cells have been found in a variety of adult tissues including 
periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle, dermis, brain, 
liver5.
Gene Markers of MSC’s through Mature Osteoblast
The hematopoietic stem cell lineage has been well characterized with specific cell 
surface markers to identify the stage of differentiation a population of cells is in.  The same 
thing has not been done with the mesenchymal stem cell lineage but is slowly being 
6discovered.  The isolation of MSC’s usually leads to a diverse and heterogeneous 
population of cells.  Mesenchymal stem cells usually express specific cell surface markers 
such as Stro1, C44, and CD105 6.  These are the most common markers but other markers 
have been identified.  If one or more of these markers are expressed then chances are there 
truly is a specific population of MSC’s.  If none of the markers are expressed, it does not 
mean there is not a specific MSC population because MSC’s are multipotent.  Some 
markers have a redundancy among cell lineages but this is not necessarily always the case. 
The reason for this is simply because the great heterogeneity and diversity MSC’s have.
Once MSC’s begin to differentiate they began to loose some of their cell surface 
markers and begin to gain osteoblast specific cell surfaces marker.  The most common 
markers for the osteoblast lineage are collagen type 1, alkaline phosphatase (ALP), and 
osteocalcin 7.  Each marker represents different stages of osteoblastogenesis as early, mid, 
and late stage, respectively.
Osteoblast Differentiation
BMP mediated
In 1965, Marshall Urist was the first to realize during his studies of bone that a partially 
purified extract of non-collagenous protein from demineralized bone matrix contained a 
potent molecule capable of inducing bone formation.  He termed this molecule bone 
morphogenetic protein (BMP).  Urist never completely isolated and purified the molecule 
which he suspected to be a potent inducer of bone.  Over the next forty years, scientist used 
similar starting materials to discover molecules that had osteogenic properties. 
7Consequently, 20 BMP’s have been identified, characterized, and named after Urist’s 
original BMP 8.  However, Urist argued that there remained a molecule within his partially 
purified extract which was not a BMP molecule.  The molecule was later identified as a 
fragment of Spp24, which migrated with the known BMP’s and enhanced its osteogenic 
potential 9.  
 Bone morphogenetic proteins are ubiquitous growth factors that are members of the 
transforming growth factor β (TGFβ) superfamily.  They have been implicated to play 
important functions in embryonic development and cellular signaling in the adult animal 8. 
Importantly, BMP’s 2 and 7 are morphogens that induce osteoblast differentiation.  In fact 
the use of recombinant BMP2 has been FDA approved for clinical purposes.  Finally, an in 
vivo study of a rodent model has shown that recombinant heterodimer BMP2/7 is an even 
more powerful morphogen than its homodimer equivalents 10.
  Signal transduction of BMP occurs when dimerized ligand bind to dimerized 
serine/threonine kinases type I and type II receptors forming a heterotetrameric activated 
receptor complex.  Afterwhich, Smad proteins 1, 5, or 8 along with co-Smad 4 relay the 
signal to the nucleus 8.  There Smad proteins activate master genes, Runx2 and Osterix, 
which control osteoblastogenesis. 
Dexamethasone mediated
As mentioned systemic hormones and local factors regulate bone remodeling.  Of 
those hormones glucocorticoids are important regulators of remodeling.  If administered in 
an excessive and continuous amount, the predominant effect in in vivo studies is to 
8increase resorption and decrease formation.  For this reason, glucocorticoids are never used 
as a continuous treatment to heal fractures or disease for clinical applications.  As 
evidence, there have been a number of studies demonstrating the long term effect of 
glucocorticoid treatments induces osteoporosis.  The mechanism of how this occurs is not 
very clear but it has been shown to decrease genes important to osteoblastogenesis such as 
IGF-1 and type 1 collagen 11.
However, Bellows et al. and later Cheng et al. demonstrated that a very low 
physiological concentration (10 nM) of dexamethasone, a synthetic glucocorticoid, was 
capable of inducing differentiation which resulted in an osteoblast phenotype using an in 
vitro model 12, 13.  The mechanism of differentiation is unknown.  There are studies that 
suggest that it may have a common pathway to BMP signaling yet, others that indicate an 
independent signaling mechanism 14.   Although there are competing theories, 
glucocorticoids such as dexamethasone provide an easy, practical, and cost effective way 
of differentiating MSC’s in vitro for a wide array of studies in the laboratory.  
Other mediators: Parathyroid hormone mediate (PTH) & Vitamin D (1,25-
hydroxycholecalciderol)
 
Parathyroid hormone is synthesized and secreted from the parathyroid gland.  It is 
the major hormone responsible for the regulation of serum calcium (Ca2+) concentration. 
When the body senses low serum Ca2+ it signals to the parathyroid gland to start secreting 
PTH.  PTH then acts on bone by increasing resorption and thereby increasing serum Ca2+. 
It also increases Ca2+ renal reabsorption, further increasing serum Ca2+.  The last method by 
9which PTH increases serum Ca2+ is through an indirect effect.  PTH stimulates production 
of vitamin D which increases Ca2+ absorption from the intestines to the extracellular fluid 
which effectively increases serum Ca2+.  
Although the effects of PTH catabolism are well known in the scientific and 
medical community, its anabolic effects are not.  Furthermore, the mechanism regulating 
its anabolic effects is not well understood.  Its most well characterized mode of action 
during molecular signaling is through the cAMP-CREB pathway which increases 
osteoblast numbers through an anti-apoptotic effect.  PTH binds the PTH recptor, a G-
protein coupled recptor, stimulates Gαs-mediated activation of adenylyl cyclase which 
stimulates cyclic-AMP (cAMP) production.  This subsequently phosphorylates and 
activates protein kinase A (PKA).  Protein kinase A is responsible for the inactivation of 
the pro-apoptotic protein Bad as well as activation of the cAMP response element-binding 
(CREB).  CREB then mediates expression of survival gene, Bcl-2 15, 16. 
Although this has been the most studied pathway other pathways may also be involved 15. 
Parathyroid hormone has been found to directly stimulate proliferation of precursor cells or 
osteoprogenitors of osteoblasts.  Additionally, the means of administration of PTH in in 
vivo studies greatly influences its catabolic versus anabolic effects.  Intermittent 
administration has been reported to have anabolic affects while increasing collagen type I 
synthesis.  The opposite holds true for the continuous administration of PTH.  Continuous 
administration causes catabolic effects and inhibition of collagen type I synthesis.
Vitamin D synthesis begins with an analog of cholesterol, 7-dehydrocholesterol.  In 
the skin when 7-dehydrocholesterol is exposed to UV radiation it becomes cholecalciferol. 
10
The product then gets hydroxylated in the liver by 25-hydroxylase.  After which it is 
further hydroxylated to its active form 1,25-hydroxycholecalciferol by 1α-hydroxylase in 
the kidney.  Vitamin D has very similar physiological functions as PTH.  Its biggest role is 
in bone mineralization by providing Ca2+ and phosphate through the remodeling process. 
It has also been shown to have direct effects on osteoblastic progenitors by inhibiting their 
proliferation 17 and mediating their differentiation 18-20.  Again, this molecule’s mode of 
action is not well understood but it is very likely that signaling occurs through the vitamin 
D receptor (VDR).
  
Secreted Phosphoprotein-24 Protein Characterization
Secreted phosphoprotein-24(Spp24) is a non collagenous, secreted bone matrix 
protein, and has a molecular mass of 24kDa in its native full length form.  It is transcribed 
from the SPP2 gene and mapped to human chromosome 2q37.1 21&22.  The transcript is 
expressed in the liver 22, kidney 23, and to some degree bone 24 (i.e. periosteum).  However, 
most of Spp24 is synthesized in the liver.  How this expression is regulated is not really 
known.  We believe Spp24 expression might be a downstream target of GH/IGF-1 
signaling axis that induces osteoblastogenesis.  Many studies have shown the impact 
GH/IGF-1 signaling axis has on the induction of osteoblastogenesis including BMP 
mediate osteoblastogenesis25-29.  However, no one has ever showed the effect of GH/IGF-1 
signaling axis in the context of Spp24 signaling.  This hypothesis merits further research 
but is not the topic of this investigation.
11
 The bovine protein sequence contains a signal peptide that directs the protein down 
the secretory pathway and a serine rich phosphorylation site.  The serine rich 
phosphorylation motif is common to other secreted phosphoproteins that are 
phosphorylated by secretory pathway protein kinases 24.  Another hypothesized function 
for the phosphorylation modification is it may signal for Spp24 cleavage to occur but 
needs further investigation.  Spp24 also has a cystatin domain that is homologous with 
members of the cystatin superfamily (cysteine/thiol protease inhibitors) such as cystatins, 
stefins, fetuins, cathelicidins, and kininogens 30 &31. Within its cystatin domain Spp24 
contains a TGF-β receptor II homology 1 domain (TRH1).  Finally, the protein contains a 
domain that slightly overlaps the cystatin domain known as the Spp24 domain.  It is unique 
only to Spp24 and is highly conserved among vertebrate species.  This domain is poorly 
characterized and much less understood. 
 Based on its cystatin sequence homology it has been predicted to have functions 
similar to members of the cysteine protease inhibitors.  Cysteine protease inhibition is 
important in bone because osteoclast are thought to release cysteine proteases such as 
cathepsins that help mediate bone resorption by breaking down collagen matrix and other 
non-collagenous proteins under acidic conditions24.  It may also play a role in the serum 
fetuin mineral complex that prevents soft tissue calcification, in particular vascular tissue 
32-34.  The cystatin domain of the fetuin mineral complex is speculated to prevent soft tissue 
calcification by binding and inhibiting the growth of Ca2+/ PO43- crystals after osteoclasts 
have freed the inorganic ions through resorption 35, 36.  This function is not only important 
in the prevention of soft tissue calcification but may also act as mineral chaperons in the 
12
vasculature that provide and deliver Ca2+ & PO43- to boney tissue that may have a need for 
ions 37.   Paul A. Price characterized fetuin mineral complex and showed it contains three 
proteins that are consistently present upon purification: fetuin-A, matrix-Gla, and Spp24 38. 
Knock outs of fetuin-A and matrix-Gla have been shown to cause gross calcification of 
soft tissues in mice.  Another protein that has similar function of inhibiting soft tissue 
calcification is osteopontin and knocking it out has the same effect. There currently is no 
knock out model for Spp24 but it is hypothesized to have a similar effect in the context of 
its association to the fetuin mineral complex.  However, in a recent study by Van den Bos 
et al. neither Spp24 nor fetuin, both molecules comprising a cystatin domain, were found 
to inhibit the activity of cysteine proteases, specifically, cathepsin B and K. 39.  This 
suggests that fetuin and Spp24 have another mechanism whereby it inhibits soft tissue 
calcification other then its proposed cysteine protease inhibition function.  Lastly, another 
predicted function is it may act as a precursor molecule like kininogens that produce 
biologically more potent molecule (e.g. bradykinin) after cleavage 24.  
Clearly, more work is necessary to unravel the biological properties of Spp24 so 
that it may one day be used as an adjuvant for bone therapies.
13
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Table 1.  Hormones, Growth Factors, and Transcription Factors 
Affecting Bone and/or Osteoblast Development
Table 1 summarizes information about the name, type, and action of various regulators of 
bone development.
15
Name Type Action
Growth Hormone (GH) Hormone Important regulator of skeletal growth.  Acts by stimulating expression of IGF-1.
Parathyroid Hormone 
(PTH) Hormone
Maintains calcium homeostasis.  It is known 
to stimulate resorption and can stimulate 
formation of bone but only when adminstered 
intermittently. 
Estrogen Hormone
Besides its hormonal effects in pubertal 
growth and osteoporotic phenotype in 
postmenopasual women deficient in estrogen 
there is evidence of it being an inhibitor of 
osteoclast resorption and stimulator of 
osteoblast proliferation.
Glucocorticoids Hormone
Can cause an osteoporotic phenotype when 
administer continuosly in vivo. However, in 
vitro MSC's can terminally differentiate into 
osteoblast.
Vitamin D Hormone
homeostasis and affects sketetal 
development as shown by knock out mice 
defient in either 25-hydroxyvitamin D -1 α-
hydroxylase, vitamine D receptor, or both.
Bone Morphogenetic 
Protein (BMP) Growth Factor
BMP family proteins play a crucial role in 
mediating growth, differentiation, and 
apoptosis in different cell types.
Insulin-like Growth 
Factor I (IGF) Growth Factor
A ubiquitous growth prompoting polypeptide 
important in regulating cellular proliferation 
and differentiation via endocrine, paracrine, 
and autocrine signaling.  Circulating IGF is 
expressed abundantly in liver and bone. 
Secreted 
Phosphoprotein-24 
(Spp24)
Growth Factor
A fragment of the protein has been shown to 
increase rate of calcification.  We have 
shown it to differentiate MSC into 
osteoblasts.
Runx2 Transcription Factor
A necessary but not suffient transcripiton 
factor for osteoblastogenesis.  May play a 
more significant role in early differentiation. 
Osterix (Osx) Transcription Factor
A zinc finger-containging transcription factor 
required for terminal differentiation of 
osteoblast. Null mice have impared 
differentiation and no bone is formed.
CHAPTER 2
DEVELOPMENT AND PRELIMINARY CHARACTERIZATION OF 
SECRETED PHOSPHOPROTEIN-24 ANTIBODY
ABSTRACT  
Since the isolation of secreted phosphoprotein-24 (Spp24) in 1995 24, not much is 
actually known about the key characteristics of the protein such as its structure, 
localization, and physiological function.  What is known about its structure is the 
homology that exists with cystatins and cathelecidins.  This reasoning is based on the 
primary sequence of bovine Spp24.  Analysis of the primary sequence has led to 
speculation that Spp24 may have similar functions as its homologs.  Over the last 14 years, 
the protein has been studied to vaguely address some of these characteristics using 
recombinant forms.  Examples of the recombinant forms are a secreted isoform of mature 
bovine Spp24 sequence with an N-terminal Met-(His)6 40or a full length mouse Spp24 
sequence with a C-terminal 3x Hemagglutinin (HA) tagged isoform as done in our lab. 
These studies have also yielded a lot of data demonstrating processing and lability of the 
protein under different conditions as well as providing some data on Spp24’s function 9, 40, 
41.  We have also shown that the protein is secreted into the extracellular peri-membranous 
space of MG-63 osteoblast-like cells using confocal fluorescence but taken all together it 
has failed to completely address these unknown characteristics.  In order to elucidate the 
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structure, localization, and physiological function of endogenous Spp24 there exist the 
need for an anti-body that recognizes the endogenous form.  This prompted us to develop 
one.
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INTRODUCTION
Secreted phosphoprotein-24, an extracellular bone matrix protein is highly 
conserved among vertebrate species.  Spp24 proteins have 50% to 90% sequence 
homology in particular the secretory peptide, the cystatin domain, and the variable arginine 
rich C-terminal region of the Spp24 domain 42.  There is also a continuous stretch of 
residues, SerSerGluGlu, which is identically conserved among 21 vertebrate species. 
Bovine Spp24, when compared to its orthologs, has a highly rich polyserine region that is 
interrupted and variable to its counterparts.  Here we describe a comparative in silico 
(ExPASy online) analysis of the primary sequence of bovine, mouse, and human spp24. 
This includes key structural features, physical, and chemical properties that allowed us to 
analyze and develop the most optimal antibody (Figure 2). 
The protein has been shown to be involved in bone turnover and neogenesis and is 
increasingly gaining more interest in the field of bone research.  New research is emerging 
suggesting that secreted phosphoprotein-24 can regulate cytokine signaling (i.e. Spp24 is 
pseudoreceptor capable of binding and modulating BMP signaling) for bone development, 
differentiation, and fracture healing 42.  Our lab has shown it to be a potent bone 
morphogen that has dual functions (i.e. inhibits and stimulates) with the BMP signaling 
interface as demonstrated by other researchers 41 & 9. 
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There is a need for a reliable and readily available anti-body that detects Spp24 to 
study structural functional relationships of the protein as well as studying the localization 
of the protein.  To this end, we developed a novel antibody using mouse sequence that can 
detect residues 170-183 which correspond to the epitope SDESRSEQFRDRSL.  Two 
rabbits, YZ27 and YZ28, where used for its development.  The two antibodies, anti-Spp24 
27A and 28B, have been characterized via ELISA and through comparison of western blots 
including an antibody developed by Brochmann-Murray et. al. which we call Murray’s 
antibody. 
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MATERIALS AND METHODS
In Silico:  Comparative Analysis of Primary Spp24 Sequence in Bovine, Mouse, and 
Human
UniprotKB/Swiss-Prot was used to find primary sequence of Spp24 from bovine, 
mouse, and human.  ExPASy alignment tool was used to find, highlight homologous 
domains, and key structural features in mouse and human sequence based on bovine 
sequence characterized by Hu et al.  Kyte & Doolittle hydrophobicity plots where done 
using ExPASy online and corroborated with the algorithms used by YenZym™.  Other 
parameters analyzed by our lab include surface probability, protein flexibility, and 
antigenic index (algorithmic data was provided by YenZym™).  
In Vivo Antibody Development
Based on the in silico analysis, the C-terminal peptide of mouse Spp24 
(CSDESRSEQFRDRSL) was the decided to be the most optimal epitope and synthesized. 
The N-terminal cysteine of the peptide was assigned for single point, site directed 
conjugation to keyhole limpet hemocyanin (KLH).  Finally, it was injected into rabbits 
YZ27 and YZ28 for antiserum production (YenZym™).
21
Characterization via ELISA
Microtiter wells are coated with 0.1 µl/ 100 µl/ well of peptide conjugated cys.-
GIgG (goat immunoglobulin) to capture antibodies.  After which, 100µl of serially diluted 
(1:1,000, 1:10,000, and 1:100,000) antiserum/antibody are added to each well and 
incubated for 30 mins at 37°C.  Each dilution was done twice to give an n=2.  This is 
followed by decanting antiserum/antibody and 2 washes with wash buffer containing PBS 
with 0.05% Tween-20.  One hundred micro liters of horse radish peroxidase HRP-
conjugated goat anti-rabbit (1:2000) was added to each well and incubated for 30 mins at 
37°C.  After a similar wash step as mentioned above, 100 µl of ABST (2,2'-azino-bis-[3-
ethylbenzthiazoline-6-sulfonic acid]) substrate solution was added to each well and 
incubated at room temperature for 10 to 20 mins.  The plate was then read at an absorbance 
of 405.  
Western Blot Detection of Spp24 with Anti-Spp24 #27A, 28B, and Anti-Murray’s
Human bone marrow derived MSCs were isolated by adherence to plastic then 
expanded and passaged three times before use in experiments. The use of these cells from 
human patients followed an approved IRB protocol. Mesenchymal stem cells with adeno-
viral mediated over-expression were lysed on days 7,8, and 9 using mammalian protein 
extraction reagent (MPER) containing Pierce Halt protease inhibitor.  Samples were then 
sonicated and centrifuged at 14,000 rpms for 15 mins. Supernatant containing solubilized 
protein was quantified via Bio-Rad Bradford protein assay and samples where diluted to 
equal concentrations of total protein.  Samples where then boiled for 5 mins at 95°C in the 
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presence of β-mercaptoethanol/Laemmli buffer.  Proteins were separated on a 12% SDS-
polyacrylamide gel and transferred onto a nitrocellulose membrane.  Membranes where 
then blocked with Licor blocking solution and incubated with primary antibody Spp24 
(1:1000 dilution).  The bound antibodies were detected with 800 nm fluorescence’s labeled 
goat anti-rabbit IgG on Licor Odyssey scanner.
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RESULTS
Antibody Development 
Murray’s antibody was made to detect the epitope having A.A. residues 175-188 of 
bovine sequence, GEPLYEPSREMRR 40.  In contrast our Spp24 27A and 28B antibodies 
were made to mouse sequence CSDESRSEQFRDRSL which correspond to A.A. residues 
170-183.  This epitope choice was the result of selecting the most optimal epitope based on 
the hydrophobicity plot, surface probability, protein flexability, and antigenic index 
(Figure 2). 
Analysis of the primary sequence revealed little homology and overlap between 
epitopes of bovine sequence versus both mouse and human sequences (Figure 3).  The 
bovine epitope was found to have a single serine and tyrosine residue where as both mouse 
and human have four serines.  Additionally, bovine epitope has two proline residues which 
are known to confer characteristic kinks or turns in the secondary structure of a protein. 
Moreover, there is a two A.A. difference between the epitopes of mouse and human 
sequence.  If exposed to both mouse and human epitopes, 27A and 28B antibodies have the 
ability to detect and cross react with each epitope.  This is not the case with the bovine 
epitope due to very little sequence homology.  This will result in little to no detection of 
mouse and human epitope. 
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ELISA 
At 20 minutes of incubation, using all three dilutions of antiserum, both 27A and 
28B antibody showed significant increase in response to the peptide cys-conjugated goat 
IgG when compared to pre-immune serum.  The most concentrated (1:1,000) forms of both 
antibodies showed the greatest response as expected (Figure 4).  From this point onward 
pre-immune serum was not used as ELISA confirmed it could not bind and detect the 
Spp24 antigen.
Western Blot Comparing Detection of Spp24 with Anti-Spp24 #27A, 28B, and Anti-
Murrays
Western blots of protein collected on days 7, 8, and 9 after overexpressing Spp24 in 
MSC’s showed 27A and 28B antibody having detection of the expected and correct size 
(24kDa) protein.  Murray’s antibody however had no marked detection of a 24kDa protein.
Finally, there is some specificity that can be confirmed with Murray’s antibody.  Detection 
of a smaller fragment of Spp24, about 18kDa in size, is seen with all three antibodies 
(Figure 5). 
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Figure 2.  In Silico: Comparative Analysis of Primary Spp24 Sequence in 
Bovine, Mouse, and Human
Source: YenZym™ Algorithms
Figure shows different plots of various properties to determine the best epitope for mouse 
Spp24 sequence including: hydrophobicity, surface probability, protein flexibility, and 
antigenic sequence.  The sequence alignment comparison of conserved A.A.’s, when 
compared to mouse sequence, is denoted by a dash.  The A.A.’s residue numbering is 
based on the mouse sequence of 203 A.A.’s. 
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Figure 3.  Sequence Alignment Stack of Primary Spp24 Sequence in 
Bovine, Mouse, and Human
ExPASy alignment tool was used to do sequence alignment. Figure contains a key with 
highlighted regions of interest. 
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Stack of three species:
Signal peptide (yellow)
Cystatin domain (+---------+)
Cysteine knots/Disulfide bridges (cyan & green)- *NOTE: From C to C is 
the TRHI domain
Serine rich sequence (underlined)
SSEE- only four residues in sequence that are identically conserved among 
21 species
Rabbit anti-mouse Spp24 27A & 28B epitope-  *NOTE: Can cross react with 
human epitope
V.S.
Murray’s Rabbit anti-bovine Spp24 epitope
                               10        20        30        40        50        60
Ruler        ---------+---------+---------+---------+---------+---------+
SPP24_BOVIN(Q27967)   ----MEKM--AMKMLVIFVLGMNHWTCTGFPVYDYDPASLKEALSASVAKVNSQSLSPYL  54
SPP24_MOUSE(Q8K1I3)   ----MEQA--MLKTLALLVLGMHYWCATGFPVYDYDPSSLQEALSASVAKVNSQSLSPYL  54
SPP24_HUMAN(Q13103)   MISRMEKMTMMMKILIMFALGMNYWSCSGFPVYDYDPSSLRDALSASVVKVNSQSLSPYL  60
                        **:    :* * ::.***::* .:*********:**::******.***********
                               70        80        90        100       110       120
Ruler        ---------+---------+---------+---------+---------+---------+
SPP24_BOVIN(Q27967)   FRAFRSSVKRVNALDEDSLTMDLEFRIQETTCRRESEADPATCDFQRGYHVPVAVCRSTV  114
SPP24_MOUSE(Q8K1I3)   FRATRSSLKRVNVLDEDTLVMNLEFSVQETTCLRDSG-DPSTCAFQRGYSVPTAACRSTV  113
SPP24_HUMAN(Q13103)   FRAFRSSLKRVEVLDENNLVMNLEFSIRETTCRKDSGEDPATCAFQRDYYVSTAVCRSTV  120
                *** ***:***:.***:.*.*:*** ::**** ::*  **:** ***.* *..*.*****
                               130       140       150       160       170       180
Ruler        ---------+---------+---------+---------+---------+---------+
SPP24_BOVIN(Q27967)   RMSAEQVQNVWVRCHWSSS-SGSS  SS  EEMFFGDILGSSTSRNSYLLGLTPDRSRGEPLYE  173
SPP24_MOUSE(Q8K1I3)   QMSKGQVKDVWAHCRWASS-SESN  SS  EEMMFGDMARSHRRRNDYLLGFLSDESRSEQFRD  172
SPP24_HUMAN(Q13103)   KVSAQQVQGVHARCSWSSSTSESY  SS  EEMIFGDMLGSHKWRNNYLFGLISDESISEQFYD  180
                ::*  **:.* .:* *:** * * *****:***:  *   **.**:*: .*.* .* : :
                               190       200       210
Ruler        ---------+---------+---------+-
SPP24_BOVIN(Q27967)   PSRE-MRRNFPLGNRRYSNPWPRARVNPGFE  203
SPP24_MOUSE(Q8K1I3)   RSLEIMRRGQPPAHRRFLNLHRRARVNSGFE  203
SPP24_HUMAN(Q13103)   RSLGIMRRVLPPGNRRYPNHRHRARINTDFE  211
                  *   ***  * .:**: *   ***:*..**
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Figure 4.  ELISA
This figure is a graphical representation of the immune response to the antigenic 
sequence elicited by 27A and 28B antibodies at 20 mins of incubation with different 
serially diluted serum solutions versus pre-immune serum in an n=2.
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Figure 5.  Comparison of Spp24 Detection with Antibodies 27A, 28B, and 
Murray’s
Western blots showing detection of Spp24’s 24 kDa protein with 27A and 28B but not 
Murray’s.  Also, all three antibodies detect similar 18kDa fragments of Spp24.
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DISSUCUSSION
The lack of an anti-body for the endogenous protein may have led Brochmann-
Murray et al. to develop one.  Brochmann-Murry et al. mentions the development of an 
anti-body that recognizes C-terminal end, residues 175-188, of bovine sequence 40. 
However, they have never included any data in the literature where they use their own anti-
body.  All of their data for detection of a 24kDa protein relies on the recombinant bovine 
Spp24 sequence with N-terminal Met(His)6 tagged protein created in E.coli. Wanting to 
know why they had not shown data with Murray’s antibody we requested and tested 
Murray’s antibody.  We found detection of an 18 kDa fragment but not full length 24 kDa. 
The inability of Murray’s to detect the 24kDa protein may be due differences in sequences 
between species and the location of where the epitope was made.  There is a small over lap 
of sequence homology upon examination of the epitopes recognized by Murray’s versus 
mouse specific 27A and 28B.  In fact, neither mouse nor human sequences have the two 
prolines that bovine sequence has.  Perhaps, the folding of bovine sequence when 
compared to mouse or human is different due to these prolines.  This may preclude 
Murray’s antibody to detect the epitopes of the native structure of mouse and human 
sequence.  However, the last three residues of the bovine epitope are identically conserved 
among all three species and this may confer a little more specificity in recognizing the 18 
kDa form of Spp24.  Furthermore, it may be possible that the epitope of 18 kDa fragment 
in mouse and human sequence is more accessible to Murray’s antibody because the protein 
is folded differently than the native 24 kDa structure.  These inconstancies raise questions 
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about the ability of Murray’s antibody to detect mature Spp24 in mouse and humans.  For 
this reason we believe our 27A and 28B antibody are better to study Spp24.
After analysis of the primary sequence of Spp24 in bovine, mouse, and human as 
well as the epitopes each antibody recognizes, it was easy to predict that Murray’s 
antibody would have difficulty in detecting endogenous level Spp24 in human MSC’s or 
over-expressed mouse Spp24.  The ELISA data showed positive results of an immune 
response by our 27A and 28B antibodies.  Taken together along with the western blot data 
we are more confident that our antibodies are better suited than Murray’s to study Spp24. 
We hope that this novel antibody can help us better understand and describe the 
localization in tissues, its properties, and a structural functional relationship of Spp24.
CHAPTER 3
LOCALIZATION, PROCESSING, AND PROPERTIES OF 
SECRETED PHOSPHOPROTEIN-24
ABSTRACT
In this study we are the first to describe the spatial localization of Spp24 in 
different tissues using immunohistochemistry (IHC) a non-collagenous bone matrix 
protein, in bone tissue and its expression in many different tissues using western blot 
analysis.  Detection of the 24 kDa protein, Spp24, was found in most tissue types including 
liver, brain, lung, kidney, spleen, testis, heart, bladder, blood, and bone upon western blot 
analysis.  However, it is important to note that bone was the only tissue with expression of 
an 18 kDa fragment of Spp24, henceforth referred to as Spp18.  This suggests that bone is 
a tissue type where Spp24 is metabolically processed and this smaller fragment is thought 
to be a biologically more potent or active molecule important for bone induction.  This idea 
of a biologically more active molecule is based on previous studies that demonstrate a 
smaller fragment of Spp24 is capable of enhancing osteogenic properities9, 42.
Furthermore, IHC of liver and kidney sections showed a specific staining pattern 
using our Spp24 antibody (Figure 7).  More importantly, both mouse bone and human 
bone marrow sections confirmed that only a subset of cells, found in bone marrow but not 
cortical bone, showed detection with Spp24 antibody (Figure 8).  The finding that Spp24 is 
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not found in the osteocytes of cortical bone but rather in precursor cells of the bone 
marrow suggests that it is an important molecule for bone development and remodeling. 
Human mesenchymal stem cells (hMSC’s) were chosen as a eukaryotic model system to 
assess expression and possible function of Spp24.  Adenoviral Spp24 overexpression of 
hMSC’s over a two week time course allowed a feasible method to study the protein due to 
low endogenous Spp24 protein expression.  The protein profile demonstrated the 
processing of Spp24 and the appearance of Spp18 at day 7.  In addition, shortly after the 
appearance of Spp18 we can see progression of hMSC’s to mature osteoblast assessed by 
matrix calcification and visualized via alizarin red stain.  The loss of detection of the 
molecule towards the end of the differentiation time course supports the hypothesis of 
mature osteoblast having no expression of Spp24 possibly because it no longer needs it and 
becomes degraded.  We then tested Spp24’s stability after being subjected to a number of 
freezing and thawing cycles at room temperature.  After which, we checked for 
degradation.  In support of the idea that proteolytic susceptibility of Spp24 may be calcium 
dependent, work done by Brochmann-Murray et al.40, we show Spp24 overexpresion in 
MSC’s lysates are degraded by 4mM calcium solution.  
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INTRODUCTION
Although Spp24’s exact function in bone biology is not yet known, there is 
evidence supporting the notion that size of the protein correlates to its role in enhancing or 
inhibiting bone morphogenetic protein (BMP) signaling. Bone morphogenetic protein is 
the common morphogen for induction of bone differentiation. Benhanm et al. 
9demonstrated a synthetic19 amino acid (BMP binding peptide or BBP), cyclic peptide 
made from Spp24’s TRH1 domain having modest BMP affinity (Kd~3 x 10-5), was capable 
of enhancing ectopic bone formation when implanted into mouse skeletal muscle.  In 
contrast, Sintuu et al. 41 provided data in which FL-Spp24 inhibits BMP-2 induced ectopic 
calcification.  Therefore, it maybe necessary for Spp24 to undergo processing into a 
smaller peptide before it can become a more bio-active molecule.
Previously, tissue specific protein expression has not been shown with this 
molecule. To address this issue we developed an anti-body to mouse Spp24 that cross 
reacts with a similar epitope on human Spp24.  We utilize the novel anti-Spp24 27a for 
immunohistochemistry and western blot analysis to further our understanding of Spp24 
and help elucidate a role for Spp24 in bone.
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MATERIALS AND METHODS 
Multi Tissues Blot 
Different organ tissues were collected from c57 black 6 mice and stored at -70°C. 
They were indivdually flash frozen with liquid nitrogen and grinded with mortar and 
pestal.  Bone was decalcified using EDTA before flash freezing.  An extraction buffer was 
prepared containing 20mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, and 1mM 
EGTA.  The buffer was then added to each organ to extract protein.  Samples were then 
sonicated and centrifuged at 14,000 rpms for 15 mins.  Supernant containing solubilized 
protein was quantified via Bio-Rad Bradford protein assay and samples where diluted to 
equal concentrations of total protein.  Samples where then boiled for 5 mins at 95°C in the 
presence of β-mercaptoethanol/Laemmli buffer.  Proteins were separated on a 12% SDS-
polyacrylamide gel and transferred onto a nitrocellulose membrane.  Membranes where 
then blocked with Licor blocking solution and incubated with primary antibody Spp24 
(1:1000 dilution).  The bound antibodies were detected with 800 nm fluorescence’s labeled 
goat anti-rabbit IgG on Licor Odyssey scanner.  
Immunohistochemistry
Paraffin sections from bone of c57 black mice were cut to 3 microns and mounted 
on slides.  Human bone marrow tissue was provided by the Department of Anatomical 
Pathology and prepared similarly.  Sections were then deparaffinized in three changes of 
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Xylene for 5 minutes each.  Rehydratiation of sections was conducted in decreasing grades 
of alcohol for 5 changes of 3 minutes each: 100% two changes, 95%, 80% and then rinsed 
in distilled water.  
Hematoxylin and Eosin Stain
After rehydration slides are stained with hematoxylin rinsed and dipped into an 
acidic alcohol solution to remove non-specific binding of the stain.  The slides were then 
rinsed and a carbonate solution is added to bring out the blue hue commonly found with 
the stain.  Eosin was used as the counter stain.  Finally slides where dehydrated, cleared 
with xylene and covered with a cover slip.
Immunohistochemistry using 27A Antibody
After rehydration slides were treated with 3% Hydrogen Peroxide containing 
sodium azide for 3 to 5 minutes to block endogenous peroxidase activity.  Paraffin slides 
required HIER (Heat Induced Epitope Retrieval) therefore placed in a steamer for heat 
targeted retrieval.  A pH of 6 was used for 20 minutes to retrieve the epitope.  Slides were 
allowed to cool for 20 minutes.  Slides were loaded onto Dako Corporation auto-
immunostainer.  Nonspecific protein binding sites were blocked by incubation in the serum 
free protein block for 5 minutes.  Slides were then rinsed for 2 minutes in Dako wash 
buffer.  Spp24 mouse specific rabbit polyclonal antibody was added to each test slide using 
an optimal dilution of 1:50 and conjugated to a secondary anti-rabbit IgG.  A negative 
control slide was also made that contained secondary alone.  Slides were then rinsed with 
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Dako wash buffer as previously mentioned.  Horseradish peroxidase (HRP) Envision+TM 
polymer was incubated with each slide and control for 20-50 minutes followed by a rinse 
step.  After the application of the HRP polymer specific antibody and conjugated polymer 
enzyme complex slides were visualized utilizing a precipitated enzyme product/substrate 
3,3'-diaminobenzidine chromogen (DAB+).   Finally, slides were counterstained using 
Gill’s III Hematoxylin for 30 seconds, dehydrated, cleared, and a coverslip was placed on 
each.  The entire procedure was done at room temperature.
Cell Culture
Human bone marrow derived MSCs were isolated by adherence to plastic then 
expanded and passaged three times before use in experiments. The use of these cells from 
human patients followed an approved IRB protocol. Human MSC’s were purified from 
primary hip patients in accordance with an approved IRB protocol.  Cells were expanded 
in culture conditions of DMEM medium containing 10% FBS, 1% P/S antibiotic and 2 
ng/ml of FGF-basic for 3 passages before switching to osteogenic conditions.  Osteogenic 
medium conditions involved removing bFGF from the DMEM and supplementing with 2 
mM ascorbic acid and 10 mM β-glycerol phosphate for a 15 day period.  The cells were 
maintained in a incubator at 37°C with a humidified atmosphere and 5% CO2 composition 
in air.
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Adenoviral Overexpression of Spp24 Time course
Human MSC’s were transduced 24 hours before day 1 using an adenovirus 
construct containing Spp24 with HA tag at a multiplicity of infection (MOI)=100. 
Mesenchymal stem cells were allowed to differentiate for a 2 week time course under 
osteogenic conditions.  Day 0 were the uninfected control cells.  Cells were lysed each day 
using mammalian protein extraction reagent (MPER) containing Pierce Halt protease 
inhibitor.  Lysates were prepared for western blot as previously mentioned and completed 
using the same conditions.  Spp24 was detected using anti-Spp24.
Spp24 Stability and Lability Assays
Spp24 Stability After Freezing and Thawing
Protein extracts from MSC’s where taken at day 9.  Cells were differentiate using 
dexamethasone.  Twenty micro-liter aliquots of protein extract where added to 5 
Eppendorf tubes and frozen at -20°C for storage.  Each tube was thawed at room 
temperature and refrozen a different number cycle ranging from 1-5 times.  Protein extracts 
were then run through a western blot as described.  To normalize α-tubulin was used as a 
loading control.
Spp24 Calcium Dependent Proteolysis Assay
Human MSC’s where transduced with Adeno-Spp24HA. Cell lystates where 
collected at 0, 1, 2, 4, 6, and 24 hrs in presence or absence of 4mM calcium solution. 
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Lysates were prepared for western blot as previously mentioned and completed using the 
same conditions.  Spp24 was detected using anti-Spp24HA (1:5000 dilution).
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RESULTS
Western blot Analysis of Multiple Tissues, Spp24 Overexpression Time course, and 
Calcium Dependent Proteolysis of Spp24
Spp24 was found to have no detection in muscle and very faint detection in 
intestines.  Most other tissues had detection including liver, brain, lung, kidney, spleen, 
testis, heart, bladder, blood, and bone.  Bone however, was the only tissue with expression 
of Spp18 (Figure 6).  To further explore the fragmentation of Spp24, hMSC’s were chosen 
as a model system whereby overexpression of Spp24 demonstrated the fragmentation 
pattern of Spp24 as cells underwent differentiation.  The western blot revealed a possible 
cleavage event beginning at day 7.  Additionally, the presence of a doublet band and Spp18 
was revealed.  Shortly after the appearance of Spp18 there was noticeable increase in 
calcification to the cellular matrix occurring at day 9 and was visualized via alizarin red 
stain (calcification data shown in Chapter 4).  The detection of 18 kDa fragment remained 
until day 12 after which complete expression were lost for both Spp24 and Spp18 (Figure 
9).  The stability and degradation of Spp24 was tested after 5 freeze and thaw cycles but 
was not affected by these conditions (Figure 10A).  To corroborate Brochmann-Murray et. 
al. findings of a calcium dependent mechanism for proteolysis of Spp24, hMSC lysates 
that had been infected with Adeno-Spp24HA  and co-incubated  with 4mM calcium. 
Lysates completely degraded after 1 hr of calcium treatment.  Also, other non-specific 
proteins where not degraded by the presences of calcium (Figure 10B).  
48
H&E and IHC Analysis
Immunohistochemistry of liver and kidney sections showed specific staining 
patterns using our Spp24 27A antibody when compared to just the application of secondary 
anti-rabbit IgG.  The liver had very high protein expression throughout most of the tissue 
except for the walls of the hepatic vein.  Spp24 was also found to localize in the kidney, 
specifically the cortex but not in the glomeruli or medulla (Figure 7).  
Hematoxylin and eosin stain of mouse bone depicted cancellous bone in purple and 
cortical bone in pink, respectively.  The IHC of mouse bone showed specific Spp24 
expression of a subset of cells in the marrow space of cancellous bone.  Based on these 
results we then went on to look at human bone marrow.  Human bone marrow also had a 
similar pattern of staining and only a specific number of cells expressed Spp24 (Figure 8).
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Figure 6.  Multi-Tissue Blot
Western blot showing detection of Spp24 with 27A Ab in different tissues. Only bone has 
expression of 18 kDa fragment. (n=1)
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Figure 7.  IHC and H&E Staining of Kidney and Liver
  For each box beginning from top left corner to right corner:  IHC with primary 
Spp24 27A Ab. Then section with secondary alone.  Bottom left corner: H&E stain 
followed by IHC with primary Spp24 27A Ab at 20x.
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Figure 8.  IHC and H&E Staining of Mouse Bone and Human Bone 
Marrow
Beginning with top left to right and ending with bottom left to right:  H&E of bone 
where cortical bone is stained with eosin (pink) and trabecular bone is stained with 
hematoxylin (bluish purple). 
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Figure 9.  Adenoviral Overexpression of Spp24 Time Course
Western blot showing 15 day time course of Spp24 processing.  Spp18 appears at 
day 7.  Both Spp24 and Spp18 detection is abolished after day 12. (n=1)
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Figure 10.  Stability and Lability Assays
A: Spp24 protein after 1 to 5 different freeze and thaw cycles.  B: Spp24 
degradation after exposure to 4mM Ca+ solution compared to no degradation of non-
specific protein.
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DISSCUSION
Transcription of Spp24 has been found in liver 22, kidney 23, and bone 24; it was 
expected that subsequent protein expression be found in these and only these tissues, using 
both IHC and western blot.  This study proved otherwise, protein detection of Spp24 was 
found in almost all tissues types and previously has not been shown.  Why detection is 
found in tissues other than where the transcript is found is not known and much less known 
about what role Spp24 plays in these other tissues.  However, a possible explanation for its 
detection in many tissues types is due to liver secretion of Spp24 into the blood stream and 
subsequently migrating to other tissues.  Elucidating a role for Spp24 in bone has been a 
central focus in our lab.  Hence, the multi-tissue blot finding of an 18 kDa cleavage 
product in bone and previous literature leads us to propose that bone is a key tissue where 
the molecule is processed and can become a metabolically active protein. 
To specify the spatial localization of Spp24 expression in bone we preformed IHC 
on mouse bone and later human bone marrow.  Interestingly, we found only a small 
population of cells positively stained Spp24 within the bone marrow of mouse but not 
cortical bone.  Furthermore, human marrow also displayed a similar staining pattern. 
Based on the absence of detection in cortical bone where mature osteoblast that later 
become osteocytes reside, we reasoned that the populations of cells that expressed Spp24 
were progenitor cells for osteoblast.  
We then decided to study the molecule in an hMSC model.  The use of an 
adenoviral-Spp24 construct in hMSC’s made it possible to highly express Spp24, which is 
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naturally low in abundance.  The western blot in which we overexpressed Spp24 during the 
differentiation time course revealed the smaller fragment, Spp18, at day 7.  Day 7 also 
illustrated the appearance of a doublet band around 24 kDa’s.  This doublet may represent 
a possible modification that in turn signals for cleavage to occur but further research is 
needed.  Shortly after the appearance of the Spp18, noticeable increase in calcification to 
the cellular matrix occurred at day 9 (data shown in Chapter 4).  This result suggests that 
Spp24 can act as a bone morphogen under osteogenic condition.  Also, detection of both 
Spp24 and Spp18 is abolished by day 12.  This may bolster the contention that in mature 
osteoblast Spp24 expression is absent.  
Secreted Phosphoprotein-24 may have its own mode of action if it is capable of 
driving differentiation under osteogenic conditions but it is not know how this works. 
However, to address its effects in combination with BMP signaling we think the time 
course data depicts the mature Spp24 as pre-bio-activated form of the molecule, much like 
kininogens.  This is followed by proteolytic step to produce Spp18 and is what we call the 
bio-activation step.  Mature Spp24 may play an inhibitory role with respects to BMP 
signaling as Sintuu et al. 41 demonstrated at the beginning of differentiation.  However, this 
inhibition may be required for the proper context of signaling cues and cellular 
environment to be established before the molecule gets processed; in other words 
bioactivated.  After which differentiation can proceed.  Post-bioactivation we clearly see 
increased calcification occurring possibly due to the smaller fragments interaction with 
BMP as demonstrate by Benham et. al.9.  To understand the dual function of Spp24 in the 
context BMP signaling differentiation further investigations are need.  
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Brochmann-Murray et. al.40 demonstrated that E. coli extracts expressing a His-
tagged form of Spp24 when combined and incubated with MC3T3-E1 cell extracts in the 
presence of calcium were susceptible to proteolysis.  But, in the absence of calcium the 
opposite was true.  In order to support the claim of a possible calcium dependent 
mechanism that is responsible for the proteolysis of Spp24 we tested our hMSC model 
sytem.  Our model system differed than theirs in that we overxpressed adeno-Spp24HA in 
a eukaryotic system but calcium conditions were the same.  Our results still confirmed the 
idea of a possible calcium dependent mechanism.  Finally, although Spp24 seems to be 
very labile, its stability after several freezing and thawing cycles seems to be unaffected.
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CHAPTER 4
SPP24 MEDIATED DIFFERENTIATION FROM 
MESENCHYMAL STEM CELL TO OSTEOBLAST
OR
Spp24 EFFECTS IN MSC MODEL
ABSTRACT
Data from our lab has shown that Spp24 can differentiate mesenchymal stem cells 
to an osteoblast.  How Spp24 achieves this phenomenon is not yet known.  Spp24 could 
play a role in the calcification of matrix and regulate genes important for this process, or 
Spp24 could be a powerful morphogen inducing MSC’s to differentiate into osteoblast 
subsequently causing osteogenic effects.  The most likely possibility is that it participates 
in both of these processes.  
This study looks at the ability of Spp24 to regulate the processes that orchestrate 
proliferation of MSC’s, differentiation of MSC’s to osteoblasts, and matrix calcification.  
Using Draq5 which is a fluorescent dye that stains nuclear DNA we compare proliferation 
rates of MSCs induced by treatment with BMP, Dexamethasone and Spp24.  The 
differentiation analysis specifically compares ALP stain/activity and matrix calcification 
assessed with Alizarin red stain.  These methods are standard ways of assessing 
differentiation.  Furthermore, similar morphological changes are noticeable after induction 
with BMP, Dex, or Spp24.  Finally, we show data where Spp24 regulates master genes, 
Runx2 and Osx, important to osteoblastogenesis.  Analyses were monitored in experiments 
throughout the days of the entire differentiation process or days 3 and 9.   Days 3 and 9 are 
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important time points because they represent what we believe to be a pre and post bio-
activation status of Spp24 protein, respectively.  Our results show that Spp24 is capable of 
regulating proliferation, genes important to osteoblast differentiation, and matrix 
calcification.
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INTRODUCTION
Recent studies on Spp24 have suggested that the TRH1 domain of Spp24 is capable 
of binding BMP ligand which is suggestive that it can modulate BMP signaling 42.  For this 
reason we wanted to investigate how Spp24 could effect BMP mediate osteoblastogenesis. 
Previously, our lab has shown that short interfering RNA targeting Spp24 (siSpp24) can 
completely abrogate BMP mediated osteoblastogenesis when compared to an off-target 
control (siCnt) during a 15 day differentiation time frame.  Runx2 and Osterix are master 
regulatory transcription factors for the osteoblastogenesis process.  Spp24 had a differential 
effect on Runx2 and Osterix. Treatment of mesenchymal stem cells with siSpp24 resulted 
in a reduced capacity of BMP to stimulate Runx2.  This was interesting in light of the fact 
that BMP is known to increase Runx2 expression in the differentiating MSC.  Osterix was 
effected differentially, as Osterix increases were unaffected by BMP.  However, baseline 
levels were almost completely abrogated.  Experts in the field who have developed knock 
out mice have reported that knock outs of one of these two genes leads to incomplete or no 
bone formation 43.  This shows the importance these two genes have in controlling 
osteoblastogenesis.  If these genes require Spp24 for proper osteoblastogenesis signaling, 
then it likely that Spp24 itself is also required for the differentiation process.
  If by silencing Spp24 we see abrogation of osteogenesis through the regulation of 
masters genes, what would happen if we over expressed Spp24 in an MSC model?  We 
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hope to demonstrate that Spp24 over-expression will lead to differentiation involving the 
regulation of master genes and matrix calcification.  These studies will give us an insight 
of how Spp24 might be causing its effects.  This understanding is central to the therapeutic 
potential it may have in bone disease and fracture healing.
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MATERIALS AND METHODS
Draq5 Proliferation Assay
Human bone marrow derived MSCs were isolated by adherence to plastic then 
expanded and passaged three times before use in experiments. The use of these cells from 
human patients followed an approved IRB protocol. Five micro molar concentration of 
Draq 5 is needed to stain nuclear DNA.  Once solution is made it is added directly to the 
media of a 6 well plate containing differentiate MSC’s.  Incorporation of dye into the cell 
takes about 30 minutes at room temperature and 5-10 minutes at 37°C.  Fluorescence 
intensity of wells is measured using Licor Odyssey scanner.
Phenotypic Marker Comparison of Differentiation Mediate by Dex, BMP, and Spp24
Alizarin Red Stain
Alizarin red solution prepared as a 1% aqueous solution: Dissolve 1 g of alizarin 
red S in 50 mL of distilled water, then dilute to 100 mL. The pH should be around 4.1-4.3 
and is heated to 50°C.   Wells containing differentiate MSC’s are fixed with 4% 
paraformaldehyde. Stain is applied for 10 minutes.  It is then washed a minimum of 3 
times with PBS to rid any non-specific staining.
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ALP stain and Activity
After induction of differentiation, cells were washed with phosphate-buffered saline 
twice (PBS), fixed with 4% paraformaldehyde, and stained for alkaline phosphatase for 10 
minutes.  Staining solution was removed and washed twice with PBS.  Then destaining 
solution of 95% ethanol was used to remove stain.  The plate reader was used to quantitate 
the absorbance of the stain in solution at 405 nm.  ALP activity was normalized using 
intensity of Draq5 fluorescence which represents total DNA content.
RT-PCR
Human mesenchymal stem cells were infected with AdLacZ or AdSpp24.  24 hours 
after infection, cells were treated with and without 10ng/mL BMP2/7, which was 
replenished every three days. After treatment, cells were lysed with Trizol reagent and 
RNA was extracted at 24-48 hours for one experiment and days 3 & 9 for the second 
experiment.  DNA protection was done via RQ1 RNAse free DNAse (Promega.)  1ug of 
RNA was reverse transcribed with Superscript II RT (Invitrogen) was performed with 
primers for hSpp24 for 35 cycles and subsequently PCR amplified with the indicated 
primer.  Osterix was amplified for 32 cycles and Runx 2 was amplified for 29 cycles. 
GAPDH was used as a loading control and was amplified for 27 cycles in all experiments. 
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RESULTS
Comparison of Proliferation and Differentiation with Different Inducers
Dexamethasone treatment showed significant increase in proliferation over control 
beginning at day 12 and a concomitant increase in calcification on day 12 (Figure 11A). 
Similar results occurred when the cells were treated with BMP or AdSpp24.  Proliferation 
of cells with BMP treatment are significantly increased on day 9 and calcification begins to 
occur around day 12.  Significant increases in proliferation occurred with Spp24 over-
expression as early as day 3 and calcification as early as day 9 (Figure 11B).
The comparison of proliferation on days 3 and 9 show Dex and Spp24 to have the 
most significant proliferative effects on day 9.  Also, BMP seems to more directly regulate 
ALP activity than the other treatments but Spp24 does have significant effects on day 9 
(Figure 11C).  For these experiments, significance was set at p<0.05.  Experiments were 
completed in an n of 3 so that statistical evaluation could be used.
Regulation of Runx2 and Osterix by BMP and Spp24 Over-expression
Taq-man based qPCR was used for a 48 hour analysis of early Runx2 expression 
after AdSpp24 treatment revealed repressed expression of Runx2 as early as 24 hours 
whereas BMP activated Runx2 by 48 hours.  Interestingly, Spp24 repressed the BMP 
enhancement of Runx2 at 24 and 48 hours (Figure 12A).  This data suggest Spp24 acts as a 
74
repressive agent towards BMP signaling during early osteoblastogenesis.  The molecular 
mechanism behind this is still unknown, however Spp24 acting as a pseudoreceptor to 
BMP has been suggested 42. 
Analysis at days 3 and day 9 of Runx2 and Osx revealed interesting data.  First, 
BMP increased Runx2 expression both at day 3 and 9, as expected.  It also increased 
Osterix expression at day 3 versus LacZ control.  As seen in the other experiment, Runx2 
was repressed by Spp24 treatment alone.  In stark contract, Spp24 seemed to increase 
Osterix expression over control at day 9.  The most intriguing part of the data came from 
the co-treatment of BMP and Spp24.  Co-treatment with both osteoblastogenic molecules 
increased expression of both Runx2 and Osterix over LacZ control at day 9 (Figure 12B). 
This could possibly be because of a different effect of Spp24 during day 9 or post bio-
activation during osteoblastogenesis.  If Spp24 is enhancing Runx2 and Osterix at day 9, it 
could explain the enhancement of BMP-mediated osteoblastogenesis.
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Figure 11.  Proliferation and Differentiation Assays
Figure A:  Shows proliferation (Draq5) and differentiation (alizarin red & ALP stains) 
following Dex treatment.
Figure B:  Shows proliferation (Draq5) and differentiation (alizarin red) following LacZ 
control, 10ng/mL BMP2/7, Ad-Spp24, and combo treatment.
Figure C:  Shows proliferation (Draq5) and differentiation (ALP activity) at days 3 and 9 
following Dex, 10ng/mL BMP2/7, and Ad-Spp24 treatment compared to control.
NOTE: All experiments are n=3
77
***
***
*
*
*
**
***
**
*
A.
B. C.
78
79
Figure 12.  Regulation of Runx2 and Osx by BMP and Spp24 Over- 
Expression
Figure A:  MSCs were infected with AdLacZ or AdSpp24.  24 hours post infection, 
cells were treated with and without BMP2/7.  24 and 48 hours after BMP treatment, RNA 
was isolated for Taq-man based qPCR measurements of Runx2 expression. (n=3)
Figure B:  MSCs were treated with either AdSpp24 or AdLacZ in the presence and 
absence of 10ng/mL BMP2/7.  RNA was extracted at days 3 and 9.  The samples were 
reverse transcribed using Superscript II (Invitrogen) PCR amplification was performed 
with primers for hSpp24 for 35 cycles.  Osterix was amplified for 32 cycles, Runx 2 was 
amplified for 29 cycles, and Trb3 was amplified for 33 cycles.  GAPDH was used as a 
loading control and was amplified for 27 cycles in all experiments. (n=1)
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DISCUSSION
Draq5 fluorescence, a marker of proliferation, increased throughout 
different time points of differentiation with BMP, Dex, and AdSpp24.  Some proliferation 
was noted as early as day 3 and as late as day12.  All three treatments also showed alkaline 
phosphatase activity, an indicator of osteoblastogenesis, and both Dex and Spp24 showed 
significant increase at day 9 with Spp24 showing a significant increase as early as day 3. 
Finally, an increase in alizarin red stain, a marker of calcium deposition, along with the 
morphological changes of the cell strongly suggests that each treatment could differentiate 
cells from MSC to osteoblast.  These studies clearly demonstrates that Spp24, like BMP 
and Dex, has osteogenic and morphogenic properties.  All treatments were capable of 
inducing proliferative effects, differentiating MSC’s, and producing a calcified matrix. 
Differences such as the onset and regulation of effects may be due to the fact that each may 
have slightly differences in their mechanism of action to achieve osteoblastogenesis and 
osteogenesis.  While the mechanism of BMP has been well studied, further exploration 
into Spp24 will have to be done before a specific mechanism can be defined. 
The most interesting thing about this study was Spp24’s ability to regulate the 
master genes of osteoblastogenesis.  Runx2 is repressed early on at day 3 and Osterix is 
enhanced at day 9, a point post bio-activation of Spp24.  Since Osterix is downstream of 
Runx2, a potential mechanism could be Spp24 activating Osterix independently of Runx2. 
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This would entail Spp24 affecting Osterix and Runx2 differently, which our results 
support.  This mechanism could explain the repression of Runx2 followed by the 
enhancement of Osterix.
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CHAPTER 5
GENERAL CONCLUSIONS
The studies presented in this thesis demonstrate the development of an anti-
body which helped determine localization of Spp24 in different tissues as well as 
understand properties and events taking place during differentiation of an osteoblast. 
These studies have also established Spp24 as a key player in the differentiation pathway of 
osteoblast.  Spp24 regulates master genes of osteoblastogenesis Runx2 and Osterix, as well 
as increasing phenotypic markers of the mature osteoblast that play a role in calcification 
of the secreted matrix.  Based on these results we were able to propose a mechanism. Our 
mechanism describes Spp24 repressing Runx2 expression.  Eventually repression is lost 
and BMP signaling can enhance Runx2 expression at day 9 or post bio-activation. 
Concomitantly, Spp24 can increase Osterix expression which leads to morphogenic and 
osteogenic effects of Spp24.  Further work is needed to completely elucidate Spp24 
mechanism of action.
Future work may include a dual tag vector system that would allow the monitoring 
of the N-terminal and C-terminal side of the protein.  This would give us better 
understanding of the protein processing taking place in the cell.  Another possibility may 
be to use FRET analysis in order to elucidate protein-protein interactions taking place 
especially in its relationship with BMP signaling.
Spp24 presents an exciting chapter in the field of tissue engineering and 
regenerative medicine as it displays a lot of potential for osteoblastogenesis and hopefully, 
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osteogenesis.  It may one day act as an adjuvant therapy along with current recombinant 
BMP techniques that aid in fracture healing.  
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